Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT )

NCT04243616 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT04243616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04243616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT )
Lead sponsor
Medical College of Wisconsin
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 5, 2020
Completion date
August 12, 2030
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

invasive breast cancer